202 related articles for article (PubMed ID: 18215275)
1. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus.
Welsch C; Domingues FS; Susser S; Antes I; Hartmann C; Mayr G; Schlicker A; Sarrazin C; Albrecht M; Zeuzem S; Lengauer T
Genome Biol; 2008 Jan; 9(1):R16. PubMed ID: 18215275
[TBL] [Abstract][Full Text] [Related]
2. Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease.
Welsch C; Shimakami T; Hartmann C; Yang Y; Domingues FS; Lengauer T; Zeuzem S; Lemon SM
Gastroenterology; 2012 Mar; 142(3):654-63. PubMed ID: 22155364
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
Zhou Y; Bartels DJ; Hanzelka BL; Müh U; Wei Y; Chu HM; Tigges AM; Brennan DL; Rao BG; Swenson L; Kwong AD; Lin C
Antimicrob Agents Chemother; 2008 Jan; 52(1):110-20. PubMed ID: 17938182
[TBL] [Abstract][Full Text] [Related]
4. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
5. In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir.
Jiang M; Mani N; Lin C; Ardzinski A; Nelson M; Reagan D; Bartels D; Zhou Y; Nicolas O; Rao BG; Müh U; Hanzelka B; Tigges A; Rijnbrand R; Kieffer TL
Antimicrob Agents Chemother; 2013 Dec; 57(12):6236-45. PubMed ID: 24100495
[TBL] [Abstract][Full Text] [Related]
6. Characterization of resistance mutations against HCV ketoamide protease inhibitors.
Tong X; Bogen S; Chase R; Girijavallabhan V; Guo Z; Njoroge FG; Prongay A; Saksena A; Skelton A; Xia E; Ralston R
Antiviral Res; 2008 Mar; 77(3):177-85. PubMed ID: 18201776
[TBL] [Abstract][Full Text] [Related]
7. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.
Sarrazin C; Kieffer TL; Bartels D; Hanzelka B; Müh U; Welker M; Wincheringer D; Zhou Y; Chu HM; Lin C; Weegink C; Reesink H; Zeuzem S; Kwong AD
Gastroenterology; 2007 May; 132(5):1767-77. PubMed ID: 17484874
[TBL] [Abstract][Full Text] [Related]
8. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.
Lin C; Gates CA; Rao BG; Brennan DL; Fulghum JR; Luong YP; Frantz JD; Lin K; Ma S; Wei YY; Perni RB; Kwong AD
J Biol Chem; 2005 Nov; 280(44):36784-91. PubMed ID: 16087668
[TBL] [Abstract][Full Text] [Related]
9. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.
Lin C; Kwong AD; Perni RB
Infect Disord Drug Targets; 2006 Mar; 6(1):3-16. PubMed ID: 16787300
[TBL] [Abstract][Full Text] [Related]
10. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.
Romano KP; Ali A; Aydin C; Soumana D; Ozen A; Deveau LM; Silver C; Cao H; Newton A; Petropoulos CJ; Huang W; Schiffer CA
PLoS Pathog; 2012; 8(7):e1002832. PubMed ID: 22910833
[TBL] [Abstract][Full Text] [Related]
11. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
Xue W; Ban Y; Liu H; Yao X
J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
[TBL] [Abstract][Full Text] [Related]
12. In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335.
Lagacé L; White PW; Bousquet C; Dansereau N; Dô F; Llinas-Brunet M; Marquis M; Massariol MJ; Maurice R; Spickler C; Thibeault D; Triki I; Zhao S; Kukolj G
Antimicrob Agents Chemother; 2012 Jan; 56(1):569-72. PubMed ID: 22024816
[TBL] [Abstract][Full Text] [Related]
13. A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants.
Ivanisenko NV; Mishchenko EL; Akberdin IR; Demenkov PS; Likhoshvai VA; Kozlov KN; Todorov DI; Gursky VV; Samsonova MG; Samsonov AM; Clausznitzer D; Kaderali L; Kolchanov NA; Ivanisenko VA
PLoS One; 2014; 9(3):e91502. PubMed ID: 24643004
[TBL] [Abstract][Full Text] [Related]
14. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.
Susser S; Vermehren J; Forestier N; Welker MW; Grigorian N; Füller C; Perner D; Zeuzem S; Sarrazin C
J Clin Virol; 2011 Dec; 52(4):321-7. PubMed ID: 21924672
[TBL] [Abstract][Full Text] [Related]
15. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.
Kammarabutr J; Mahalapbutr P; Nutho B; Kungwan N; Rungrotmongkol T
J Mol Graph Model; 2019 Jun; 89():122-130. PubMed ID: 30884449
[TBL] [Abstract][Full Text] [Related]
16. [Telaprevir resistance].
Poveda E; García F
Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():26-32. PubMed ID: 24063900
[TBL] [Abstract][Full Text] [Related]
17. Comparative molecular dynamics simulation of Hepatitis C Virus NS3/4A protease (Genotypes 1b, 3a and 4b) predicts conformational instability of the catalytic triad in drug resistant strains.
Kramer M; Halleran D; Rahman M; Iqbal M; Anwar MI; Sabet S; Ackad E; Yousef MS
PLoS One; 2014; 9(8):e104425. PubMed ID: 25111232
[TBL] [Abstract][Full Text] [Related]
18. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.
Susser S; Welsch C; Wang Y; Zettler M; Domingues FS; Karey U; Hughes E; Ralston R; Tong X; Herrmann E; Zeuzem S; Sarrazin C
Hepatology; 2009 Dec; 50(6):1709-18. PubMed ID: 19787809
[TBL] [Abstract][Full Text] [Related]
19. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
He Y; King MS; Kempf DJ; Lu L; Lim HB; Krishnan P; Kati W; Middleton T; Molla A
Antimicrob Agents Chemother; 2008 Mar; 52(3):1101-10. PubMed ID: 18086851
[TBL] [Abstract][Full Text] [Related]
20. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo.
Hiraga N; Imamura M; Abe H; Hayes CN; Kono T; Onishi M; Tsuge M; Takahashi S; Ochi H; Iwao E; Kamiya N; Yamada I; Tateno C; Yoshizato K; Matsui H; Kanai A; Inaba T; Tanaka S; Chayama K
Hepatology; 2011 Sep; 54(3):781-8. PubMed ID: 21626527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
